Please assess the completion status of the following clinical trial:

Trial Title: Adefovir Dipivoxil In Compensated Chronic Hepatitis B Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Have compensated chronic hepatitis B.~* Have not been treated with anti HBV agents with antiproliferative activity against. However, previous Interferon (IFN) therapy is permitted.~* Ability to read, understand, and sign the informed consent.~* Have a positive serum HBV-DNA \>= 1,000,000 copies/mL and ALT level 50-500 U/L~Exclusion criteria:~* Having or suspected of having liver cancer.~* Co-infected with Hepatitis C virus (HCV) or Human Immunodeficiency virus (HIV).~* Autoimmune hepatitis.~* Received any previous transplantation or having a plan for any transplantation.~* Existence of any serious complication, except hepatitis B.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Adefovir Dipivoxil (ADV) (Type: EXPERIMENTAL): None
- Lamivudine (LAM) (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).